Stocks and Investing Stocks and Investing
Tue, June 29, 2021
Mon, June 28, 2021

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $140 on, Jun 28th, 2021


Published on 2024-10-27 17:04:23 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $176 to $140 on, Jun 28th, 2021.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 3 other peers that have a rating on BTAI. Out of the 3 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Raghuram


  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $125 on, Wednesday, June 23rd, 2021
  • Anita Dushyanth of "Berenberg" Initiated at Strong Buy and Held Target at $75 on, Friday, April 9th, 2021
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, April 1st, 2021
Contributing Sources